Mass drug administration to reduce malaria incidence in a low-to-moderate 1

endemic setting: short-term impact results from a cluster randomised 2

controlled trial in Senegal 3

4 **Authors:**

- El-hadji Ba Konko Ciré, PhD^{1*}, Michelle E. Roh, PhD^{2,3*}, Abdoulaye Diallo, MD¹, Tidiane 5
- Gadiaga, MD⁴, Amadou Seck, MS¹, Sylla Thiam, MD¹, Seynabou Gaye, MD⁵, Ibrahima Diallo, 6
- PharmD⁵, Aminata Colle Lo, PhD¹, Elhadji Diouf, MPH¹, Omar Gallo Ba, MD¹, Alioune Badara 7
- Gueye, MD⁶, Ari Fogelson, MSc⁷, Xue Wu, MMed^{2,3}, Prof Paul Milligan, PhD⁷, Tabitha Kibuka, MPH², Moustapha Hama, MHA², Erin Eckert, PhD², Julie Thwing, MD⁸, Adam Bennett, PhD^{2,9}, 8
- 9
- Prof Roly Gosling, MD^{2,3,10}, Jimee Hwang, MD^{11,12}, Doudou Sene, MD⁵, Fatou Ba, PhD⁵, Bayal Cissé, MD⁴, Katharine Sturm-Ramirez, PhD¹³, Michelle S. Hsiang, MD^{2,3†}, Prof Jean Louis 10
- 11
- Ndiave, $MD^{1\dagger}$ 12

Author Affiliations: 13

- ¹ Université Iba Der Thiam de Thiès, Thiès, Senegal 14
- ² US President's Malaria Initiative Impact Malaria, Washington DC, USA 15
- ³ Institute for Global Health Sciences, University of California, San Francisco, USA 16
- ⁴ District of Tambacounda, Ministry of Health and Social Action, Tambacounda, Senegal 17
- 18 ⁵ Senegal National Malaria Control Programme, Ministry of Health and Social Action, Dakar,
- Senegal 19
- ⁶ US President's Malaria Initiative, United States Agency for International Development, Dakar, 20 21 Senegal
- ⁷ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 22
- 23 Medicine, London, UK
- ⁸ Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA 24
- ⁹ PATH, Seattle, Washington, USA 25
- ¹⁰ Department of Disease Control, London School of Hygiene and Tropical Medicine, London 26 27 UK
- ¹¹ US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and 28
- 29 Prevention, Atlanta, Georgia, USA
- ¹² United States Public Health Service, Rockville, MD, USA 30
- ¹³ US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and 31
- 32 Prevention, Dakar, Senegal, USA
- * Contributed equally 33
- [†]Contributed equally 34

35 **Corresponding authors:**

Michelle E. Roh **UCSF** Institute for Global Health Sciences 550 16th Street, 3rd Floor San Francisco, CA 94158, USA Email: michelle.roh@ucsf.edu

El-hadji Konko Ciré Ba Université Iba Der Thiam de Thiès Grand Standing, Thiès BP: A967 Thiès Email: el-hadj.ba@ird.fr

36 Summary

37 Background

- 38 In Africa, the scale-up of malaria control interventions, including seasonal malaria
- 39 chemoprevention (SMC), has dramatically reduced malaria burden, but progress toward malaria
- 40 elimination has stalled. We evaluated mass drug administration (MDA) as a strategy to
- 41 accelerate reductions in malaria incidence in Senegal.

42 Methods

- 43 We conducted an open-label, cluster-randomised controlled trial in a low-to-moderate
- 44 transmission setting of Tambacounda, Senegal. Eligible villages had a population size between
- 45 200–800. All villages received pyrethroid-piperonyl butoxide bednets and proactive community
- 46 case management of malaria at baseline. Sixty villages were randomised 1:1 to either three
- 47 cycles of MDA with dihydroartemisinin-piperaquine+single-low dose primaquine administered
- 48 to individuals aged \geq 3 months, six-weeks apart starting the third week of June (intervention), or
- 49 standard-of-care, which included three monthly cycles of SMC with sulfadoxine-
- 50 pyrimethamine+amodiaquine administered to children aged 3–120 months starting end of July
- 51 (control). MDA and SMC were delivered door-to-door. The primary outcome was clinical
- 52 malaria incidence in all ages assessed during the peak transmission season (July-December), the
- 53 year after intervention. Here, we report safety, coverage, and impact outcomes during the
- 54 intervention year. The trial is registered at ClinicalTrials.Gov (NCT04864444).

55 Findings

- 56 Between June 21, 2021 and October 3, 2021, 6505, 7125, and 7250 participants were
- administered MDA and 3202, 3174, and 3146 participants were administered SMC across
- 58 cycles. Coverage of ≥ 1 dose of MDA drugs was 79%, 82%, and 83% across cycles. During the
- transmission season of the intervention year, MDA was associated with a 55% [95% CI: 28%–
- 60 72%] lower incidence of malaria compared to control (MDA: 93 cases/1000 population; control:
- 61 173 cases/1000 population). No serious adverse events were reported in either arm.

62 Interpretation

- 63 In low-to-moderate malaria transmission settings with scaled-up malaria control interventions,
- 64 MDA with dihydroartemisinin-piperaquine+single-low dose primaquine is effective and well-
- tolerated for reducing malaria incidence. Further analyses will focus on the sustainability of this
- 66 reduction.

67 Funding

68 United States President's Malaria Initiative

69 Keywords

- 70 mass drug administration; seasonal malaria chemoprevention; dihydroartemisinin-piperaquine;
- 71 primaquine; sulfadoxine-pyrimethamine; amodiaquine; Plasmodium falciparum; malaria;
- 72 Senegal; transmission
- 73 Word Count: Summary (300); Manuscript (4488)

74 **Research in context**

75 Evidence before this study

76 The current World Health Organization (WHO) guidelines recommend that malaria programmes 77 consider mass drug administration (MDA) for *Plasmodium falciparum* transmission reduction in 78 low-to-very low transmission settings (broadly defined as parasite prevalence <10% or annual 79 malaria incidence of <250 cases per population). In moderate-to-high transmission areas, MDA 80 is recommended for rapid reduction of disease burden, but not for transmission reduction due to 81 the lack of published studies demonstrating its short- or long-term benefits. Among the numerous 82 studies that contributed to this recommendation, five evaluated the antimalarial combination, 83 dihydroartemisinin-piperaquine + single low-dose primaquine. However, none of the studies 84 were conducted in countries implementing seasonal malaria chemoprevention as part of their routine malaria control strategy. 85

- 86 On January 23, 2024, we conducted a PubMed search using the following term: "mass drug
- 87 administration" AND "dihydroartemisinin-piperaquine". We found one additional cluster
- 88 randomised controlled trial conducted in a moderate transmission setting of The Gambia (an
- 89 SMC-implementing country), that evaluated mass drug administration with the antimalarial
- 90 combination, dihydroartemisinin-piperaquine + ivermectin. This study demonstrated that MDA
- 91 was associated with a 70% reduction in the odds of PCR-confirmed malaria two months after the
- 92 last round of MDA. However, given the study demonstrated little evidence on entomological
- 93 outcomes, authors concluded that much of the observed effect of MDA was likely attributable to
- 94 the antimalarial efficacy of dihydroartemisinin-piperaquine.

95 Added value of this study

- 96 Our study adds to the current evidence base demonstrating the benefits of MDA with
- 97 dihydroartemisinin-piperaquine + single-dose primaquine on malaria burden reduction and may
- 98 have impacts on short-term transmission. Combined with The Gambia trial results, our study
- 99 provides new evidence demonstrating that MDA with dihydroartemisinin-piperaquine can have
- 100 short-term benefits on transmission in low and moderate transmission settings where malaria
- 101 transmission is highly seasonal.

102 Implications of all the available evidence

- 103 As countries in sub-Sahelian and Sahelian Africa progressively scale-up their malaria control
- 104 interventions, they will reach a plateau where no further gains can be made. In low and moderate
- transmission settings, MDA is a well-tolerated and effective intervention for rapidly reducing
- 106 malaria burden and may have an impact on transmission in the short-term.

107 Introduction

- 108 Malaria is a major public health concern in Africa. In regions where transmission is highly
- seasonal, seasonal malaria chemoprevention (SMC) has been widely adopted to prevent
- 110 morbidity and mortality in children at-risk of severe malaria. SMC involves the monthly
- administration of sulfadoxine-pyrimethamine + amodiaquine given during the peak transmission
- season to treat existing parasitaemia and prevent new infections.¹ Since its initial
- recommendation by the World Health Organisation (WHO) in 2012, SMC has expanded to 18
- 114 African countries, covering 53 million children in 2023.² The scale-up of SMC has been
- successful, demonstrating reductions in childhood clinical malaria incidence by 60-88% under
- **116** programmatic conditions.^{1,3}
- 117 Through high coverage of SMC, strong vector control, and prompt case management, countries
- in Sahelian and sub-Sahelian Africa have made significant strides in controlling malaria,
- prompting many to establish new goals for malaria elimination. However, recent progress toward
- elimination has stalled,⁴ necessitating enhanced coverage of proven core interventions and the
- 121 consideration of new interventions to rapidly reduce transmission. One promising approach is
- mass drug administration (MDA), which involves the administration of antimalarials to all
- individuals in a defined geographic area at a frequency and duration tailored to the local malaria
- epidemiology and goals. For MDA to have an impact on transmission, high coverage $(\geq 80\%)^{5,6}$
- of the target population is needed, which requires an optimized delivery approach and strong community engagement.⁷ Achieving high coverage may be less challenging in countries
- 126 community engagement. Achieving high coverage may be less chanenging in countries 127 successfully implementing SMC, as they can leverage their existing infrastructure of door-to-
- door delivery and community and health system acceptance of chemoprevention.^{8,9}
- door derivery and community and nearth system acceptance of chemoprevention.
- 129 In addition to attaining high coverage, the effectiveness of MDA depends on the type of
- 130 antimalarial regimen used. In *Plasmodium falciparum*-dominant regions, dihydroartemisinin-
- 131 piperaquine is an attractive agent for MDA given its good safety profile, long prophylactic
- 132 period, and relatively low-levels of artemisinin resistance in Africa.^{10,11} However,
- 133 dihydroartemisinin-piperaquine has no known efficacy against mature gametocytes^{12,13}—the
- 134 parasites responsible for human-to-mosquito transmission. Single low-dose primaquine is a
- gametocytocidal agent shown to be safe and associated with the near complete prevention of
- human-to-mosquito transmission.^{14,15} It is likely that the combination of these drugs may confer
- 137 greater benefits than dihydroartemisinin-piperaquine alone, allowing MDA to have a greater
- 138 impact on transmission.
- Here, we present results from a cluster randomised controlled trial assessing the safety, coverage,
- and short-term impact of three cycles of MDA with dihydroartemisinin-piperaquine + single
- 141 low-dose primaquine on *P. falciparum* incidence and prevalence during the intervention year.
- 142 This study aimed to fill a critical evidence gap regarding the effectiveness of MDA to rapidly
- reduce malaria burden in a highly seasonal, low-to-moderate transmission setting where malaria
- 144 control measures have been scaled-up and additional interventions are needed to accelerate
- 145 malaria elimination.

146 Methods

147 Study setting

- 148 The study was conducted in Tambacounda Health District of southeastern Senegal (Appendix
- **1**49 **1**). The district is comprised of 523 villages with an estimated population size of 297,761 in
- 150 2020. In southeastern Senegal, malaria transmission is low-to-moderate (50–200 cases per 1000
- 151 population) and highly seasonal, with most cases occurring between July and December. In this
- 152 region, the national malaria programme (*Programme National de Lutte contre le Paludisme*;
- 153 PNLP) implements standard malaria control interventions including routine distribution of
- insecticide-treated nets, malaria case management at health facilities, SMC to children 3–120
- months of age (except those with a severe/chronic illness, known hypersensitivity to SMC drugs, and history of antimalarial receipt in the prior three weeks), and proactive community case
- management of fever through the *Prise en Charge à Domicile Plus* (PECADOM+) model. In the
- 158 PECADOM+ model, community health workers, known as dispensateur de soins à domiciles
- 159 (DSDOMs), conduct weekly household visits to identify and treat suspected malaria cases during
- 160 the malaria transmission season. Despite scale-up of these interventions, progress toward
- 161 transitioning these zones to pre-elimination status has been slow. Thus, in these areas, the
- 162 program needs an accelerator intervention to aggressively push the elimination margins and meet
- 163 the national goal to eliminate malaria by 2030.

164 Study design and participants

- 165 The study employed a two-arm, open-label, cluster randomised controlled trial design. Sixty
- villages were randomly selected for participation. Villages were eligible if they had a population
- size between 200–800; were located within a health post catchment area with an annual malaria
- 168 incidence of 60–160 cases/1000 population; and had an established PECADOM+ system or the
- 169 PEACDOM+ model was planned for implementation in the village. Villages were selected so
- 170 that village centroids were ≥ 2.5 km apart.
- 171 Participant eligibility was assessed prior to each MDA cycle. Residents of intervention villages
- 172 were eligible for MDA if they were ≥ 3 months of age and excluded if they reported a
- 173 severe/chronic illness, had a known hypersensitivity to study drugs, were pregnant (confirmed by
- urine test), had taken drugs that could influence cardiac function or prolong QTc interval, or
- received antimalarials in the prior three weeks. Children <2 years of age and breastfeeding
- 176 women were further excluded from receiving single low-dose primaquine. No SMC was
- 177 provided during the intervention year in intervention villages.
- 178 Written informed consent was obtained before the first MDA cycle and cross-sectional surveys.
- 179 Parental written informed consent was obtained from participants <18 years of age and written
- 180 informed assent was obtained from children 13–17 years of age.
- 181 Ethical approval of this trial was granted by the Comité National d'Ethique pour la Recherche en
- 182 Santé (CNERS) of Senegal and the University of California, San Francisco (UCSF) Human
- 183 Research Protection Program. The U.S. Centers for Disease Control and Prevention approved
- reliance on UCSF. The trial was registered with ClinicalTrials.gov (NCT04864444) and
- 185 oversight was provided by an independent data safety monitoring committee and external
- 186 monitor. An interim safety analysis was conducted after the first MDA cycle.

187 Randomisation and masking

188 Study villages were randomised 1:1 to intervention or control. To ensure adequate balance with respect to specified variables, villages were stratified based on whether PECADOM+ was 189 190 present at baseline. Then a constrained randomisation approach was undertaken using the 191 following village-level covariates: health post of village, distance to health post, baseline malaria 192 prevalence (assessed through a survey conducted at the end of the pre-intervention transmission 193 season), village population size, and population size of children <10 years. A study investigator 194 (MER) randomly generated intervention assignment. Participants, field team, and investigators 195 were unblinded to allocation assignment. Laboratory technicians were blinded to intervention 196 assignment.

197 Procedures

198 Community mobilisation and sensitisation

Upon village selection, the study team held meetings with administrative, health, and religiousleaders of Tambacounda Health District to discuss the study aims, planned activities, and receive

201 consent for study implementation. Community sensitisation materials were developed by the

study team and implemented by local health staff. In the months prior to MDA, which coincided

with the peak COVID-19 pandemic, additional social media campaigns, local community radio

announcements, and television advertisements were conducted. Prior to each MDA cycle, town

hall meetings and household visits were undertaken to ensure that the community was well-

206 informed.

207 Interventions

208 In the control arm, the standard-of-care chemoprevention (which consisted of three cycles of

209 SMC with sulfadoxine-pyrimethamine + amodiaquine) was administered to children aged 3-120

210 months at four-week intervals, initiated at the presumed start of the malaria transmission season.

211 In the intervention arm, three cycles of MDA with dihydroartermisinin-piperaquine + single low-

dose primaquine were administered to individuals aged ≥ 3 months at six-week intervals. To

achieve maximal impact on clearing the infectious reservoir,^{16,17} MDA was initiated one month

214 prior to the presumed start of the transmission season (**Figure 1**). Prior to intervention

215 implementation, pyrethroid-piperonyl butoxide (PBO) bednets were distributed door-to-door to

all study villages and year-round PECADOM+ was established to monitor malaria incidence.

217 MDA and SMC were delivered door-to-door by DSDOMs via directly observed therapy for all

three doses. Study drugs were administered using an age-based dosing strategy per

219 manufacturer's instructions (Appendix 2). For each MDA cycle, dihydroartemisinin-piperaquine

220 (Eurartesim[™], Sigma-Tau, Italy) was given for three consecutive days and single low-dose

221 primaquine (Remedica Ltd, Limassol, Cyprus) was given with the first dose of

222 dihydroartemisinin-piperaquine. For each SMC cycle, amodiaquine (Fosun Pharma, Shanghai,

223 China) was given for three consecutive days and sulfadoxine-pyrimethamine (Fosun Pharma,

224 Shanghai, China) was given with the first dose of amodiaquine. For participants who were

- unable to swallow tablets (e.g., young children), tablets were crushed and mixed in water. If the
- participant vomited within 30 minutes of administration, the full dose was re-administered. If the
- re-administered dose was vomited within 30–60 minutes, half the dose was administered.
- 228 During drug administration, individuals with symptomatic malaria confirmed by a histidine-rich
- 229 protein 2-based rapid diagnostic test (RDT) (ParaHIT®-f, ARKRAY Healthcare Pvt Ltd, Surat,
- 230 India) were treated with artemether-lumefantrine and did not receive study drugs until the
- subsequent cycle.
- 232 Malaria surveillance
- 233 Malaria cases were captured through health facility and PECADOM+ registries. Suspected cases
- 234 (i.e., presentation of fever or history of fever in the past 48 hours) were confirmed by RDT. To
- ensure high-quality capture of incident cases, PECADOM+ was expanded year-round
- implementation in all study villages and fully scaled-up by March 1, 2021. Data were collected
- on paper-based registries and abstracted onto electronic databases. Duplicates between registries
- were removed. Village-level population size was estimated by averaging estimates from two
- censuses conducted before-and-after intervention implementation (Figure 1).
- 240 Pharmacovigilance
- 241 Passive and active pharmacovigilance systems were used to monitor the safety of MDA. For
- 242 passive surveillance, adverse events (AEs) following drug intake were recorded by study staff or
- 243 DSDOMs into standardised case report forms. Participants were encouraged to inform local
- health or study staff if they experienced an AE within one month after drug intake. AEs weregraded by a study clinician (e.g., mild, moderate, or severe) and managed free of charge. For
- active surveillance monitoring, the study staff surveyed 220 random households per study arm on
- the day after the last dose of study drugs. Households were sampled from every village,
- 248 proportionate to village population size, such that five households were sampled from villages
- with <300 residents and ten households from villages with ≥ 300 residents. In intervention
- villages, the study team randomly sampled three members per household according to their age
- 251 group: <5, 5–15, and \ge 15 years. In control villages, three household members <10 years of age
- were randomly sampled. Survey participants were asked if they experienced an AE and to
- describe the event, including type, onset date, and duration. Severity was graded by a study
- 254 clinician.

255 Cross-sectional surveys

- 256 To determine parasite prevalence, cross-sectional surveys were conducted at the end of the
- transmission season before-and-after intervention implementation (December 10–20, 2020 and
- 258 December 9–21, 2021). A two-stage cluster sampling strategy was undertaken to randomly select
- 259 households and household members from all villages. Participants were asked about their
- 260 demographic characteristics, malaria prevention measures, and history of fever. Suspected
- 261 malaria cases were confirmed by RDT and those with a positive test were treated with
- artemether-lumefantrine. A fingerprick blood sample was taken for microscopy and for dried
- blood spots (DBS) to confirm parasitaemia by PCR and to genotype drug resistance markers.

264 Laboratory analysis

265 Microscopy slides and DBS from surveys were transported to Université Iba Der Thiam de

266 Thiès. Slides were stained with 6% Giemsa for 20 min and read by two microscopists. A third

- reviewer settled discrepant findings. Parasite DNA was extracted from DBS using the Chelex-
- 100 extraction method¹⁸ and tested for parasitemia by real-time PCR using species-specific
 primers based on 18s rRNA gene as previously described.¹⁹ PCR-positive samples were
- 270 genotyped to assess the presence of point mutations in the *pfK13*, *pfdhps*, *pfdhfr*, *pfcrt*, and
- pfmdrl genes using high-resolution melting analysis as previously described.²⁰

272 Study outcomes

- 273 The primary outcome of the trial was village-level malaria incidence in the year after
- intervention implementation. Here, we report the impact of MDA on incidence during the
- transmission season of the implementation year. Village-level malaria incidence was defined as
- the number of RDT-confirmed symptomatic malaria cases detected through health post and
- 277 PECADOM+ surveillance divided by the average village population size obtained from two
- censuses performed before-and-after intervention implementation (**Figure 1**). Secondary
- outcomes included parasite prevalence by microscopy and PCR, coverage and safety of MDA,
- and prevalence of drug resistance markers assessed through cross-sectional surveys.
- 281 Coverage was defined according to WHO guidelines⁷. For each chemoprevention campaign, a
- 282 pre-intervention census was used to generate a registry that determined who would be targeted
- for each cycle. Data on adherence and dose were recorded for each person and day. The registry
- 284 was updated throughout the campaign to identify new residents, deaths, and emigrants. Both
- crude and distributional coverage are reported. Crude coverage was defined as the proportion of
- residents who received ≥ 1 dose of study drugs among study residents. Denominator included
- absences, refusals, and those who did not meet the eligibility criteria. Distribution coverage was
- 288 defined as the proportion of residents who received ≥ 1 dose among eligible residents, thereby
- excluding pregnant women and those with a self-reported illness. Both coverage metrics
- excluded deaths and emigrants.

291 Statistical analysis

- All analyses were conducted using Stata version 17.0 or R version 4.2.2. Sample size
- 293 calculations were based on detecting a 50% relative difference in RDT-confirmed malaria
- incidence between arms in the year post-intervention. We assumed mass distribution of
- 295 pyrethroid-PBO bednets, SMC, and scale-up of community case management would
- cumulatively reduce annual malaria incidence by 50% in the control arm from 100 to 50
- 297 cases/1000 population before-and-after intervention implementation. Based on a coefficient of
- variation of 0.80 and an average cluster size of 250, a sample size of 60 clusters provided 80%
- power (using a 5% significance level) to detect a 50% relative difference in the MDA arm
- 300 (intervention effect) using a two-tailed alpha test.

301 Analyses were carried out using an intention-to-treat approach. Intervention impact on incidence

- was assessed using mixed-effects Poisson regression with village-level random intercepts. In the
- unadjusted model, the following indicator variables were included: a treatment indicator that
- equalled 1 in intervention villages during the implementation year and 0 otherwise and a timevariable that equalled 1 during the implementation year and 0 otherwise. Adjusted analyses
- included covariates used in the stratified constrained randomization scheme. Intervention impact
- 307 was defined as the percent reduction in incidence between July and December in the intervention
- arm compared to the control arm (1–incidence rate ratio (IRR_{intervention})*100%). Intervention
- 309 effects on parasite prevalence were estimated using Poisson regression with robust standard
- errors. Survey weights accounting for number of households and household size were
- 311 incorporated into prevalence analyses. Prespecified subgroup analyses were conducted by age
- group (e.g., \geq or <10 years of age), DSDOM presence at baseline, and baseline transmission
- intensity (low versus moderate; low defined as parasite prevalence <10% as defined by WHO¹)
- 314 using two-way interaction terms between treatment and subgroup variables.

315 **Results**

Between September 1, 2020 and October 25, 2020, 523 villages in the study area were

- geolocated and screened for eligibility, and 111 met the inclusion criteria (Figure 2). Of these,
- 60 villages were randomly selected allowing for a ≥ 2.5 km distance between village centroids
- and randomised to intervention or control. Village-level factors included in the constrained
- 320 randomisation were balanced across arms (**Table 1**). Overall, coverage of pyrethroid-PBO
- bednets was high (98%) and similar between arms. In the pre-intervention year, 81% of children
- 322 <10 years of age reported receiving the most recent cycle of SMC and 71% reported receiving all
- three cycles. Twenty percent reported sleeping away from their home in the past 15 days.
- In the intervention arm, 8931, 9571, and 9703 residents were screened for the first, second, and
- third cycle of the MDA campaign. Distribution coverage of single low-dose primaquine (where
- the denominator excluded ineligible residents) was 79% (6286/7992), 82% (6949/8462), and
- 327 84% (7199/8575) across the three cycles. Distribution coverage of ≥ 1 dose of
- dihydroartemisinin-piperaquine among the eligible individuals was 79% (6505/8229), 82%
- 329 (7125/8673), and 83% (7250/8690) in the first, second, and third cycles. Distribution coverage of
- all three doses of dihydroartemisinin-piperaquine was 74%, 79%, and 81% across cycles.
- 331 Distribution coverage was higher in those <10 years compared to ≥10 years (distribution
- coverage of ≥ 1 dose was 85%, 86%, and 87% in <10 years across cycles, and 75%, 80%, and
- 81% in ≥ 10 years across cycles). Crude coverage of ≥ 1 dose of dihydroartemisinin-piperaquine
- was 73%, 74%, and 75% across cycles. By village, distribution coverage ranged from 58%–97%;
- 50%, 67%, and 70% of intervention villages reached the WHO target coverage of $\ge 80\%$ in the
- first, second, and third cycles, respectively (Appendix 3). The major reasons for non-
- participation were absence (range: 14%–21%) and illness (range: 5%–7%) (**Appendix 4**).
- Absences were similar between males and females (1.12:1 ratio) and in age to those who
- received MDA (16 years [interquartile range (IQR): 7–26] versus 13 years [IQR: 6–27]).
- Refusals were rare (1%-2%) and mostly among males (70%) with a median age of 22 years
- 341 [IQR: 15–30].

- In the control arm, 3492, 3489, and 3487 children aged 3–120 months were screened for the first,
- second, and third SMC cycle. Distribution coverage of ≥ 1 dose of SMC drugs was 93%
- 344 (3202/3457), 92% (3174/3442), and 92% (3146/3434) across cycles. Distribution coverage for
- all three SMC doses was 92%, 92%, and 91% across cycles. Crude coverage of ≥ 1 dose was
- 346 92%, 91%, and 90% across cycles. By village, distribution coverage ranged from 62%–100%;
- 347 93% of SMC villages reached \geq 80% coverage across all cycles (**Appendix 3**). Major reasons for
- non-receipt of SMC were absence (7%) and illness (1%–2%) (**Appendix 4**). Refusals of SMC
- 349 were low across cycles ($\leq 1\%$).
- 350 During the pre-intervention transmission season (July-December 2020), malaria incidence was
- 181 and 204 cases/1000 population in the intervention and control arms, respectively (**Table 2**).
- In the transmission season of the intervention year (July-December 2021), malaria incidence
- reduced to 93 cases/1000 population in the intervention arm and to 173 cases/1000 population in
- the control arm (**Table 2; Figure 3**). The unadjusted intervention effect of MDA was 52% [95%
- 355 CI: 21%, 71%]. The adjusted intervention effect, which accounted for variables included in the
- constrained randomisation was 55% [95% CI: 28%, 72%].
- 357 Pre-specified subgroup analyses showed evidence of an interaction by age group; the adjusted
- intervention effect was 58% [95% CI: 33%, 74%] in the \geq 10 years age group and 46% [95% CI:
- 10%, 67%] in the <10 years age group ($p_{interaction}=0.016$) (**Table 2; Figure 3**). The impact of
- 360 MDA on malaria incidence was similar in low and moderate transmission settings defined as
- 361 microscopy parasite prevalence of <10% versus $\ge 10\%$ (adjusted intervention effect=55% [31%,
- 362 71%] versus 52% [-19%, 81%]; p_{interaction}=0.88) (**Table 2; Figure 3**).
- By microscopy, parasite prevalence decreased between 2020 and 2021, from 6.1% to 1.8% in the
- intervention arm and from 6.7% to 4.7% in the control arm (adjusted intervention effect=62%)
- 365 [95% CI: 22%, 80%]) (**Table 3**). The impact of MDA differed between the <10 and ≥10 years
- 366 age group (adjusted intervention effect=76% [95% CI: 42%, 90%] versus 51% [95%% CI: -14%,
- 367 79%]), but this finding did not reach statistical significance ($p_{interaction}=0.17$). By PCR, parasite
- 368 prevalence decreased between 2020 and 2021, from 17.9% to 4.5% in the intervention arm and
- 369 19.9% to 8.3% in the control arm (adjusted intervention effect=47% [95% CI: 3%, 71%]). The
- **370** effect of MDA differed between the <10 and ≥10 years age groups: adjusted intervention
- 371 effect=71% [95% CI: 35%, 87%] and 33% [95% CI: -27%, 65%], respectively ($p_{interaction}=0.050$).
- The impact of MDA on microscopy- or PCR-confirmed parasite prevalence did not significantly
- differ between low and moderate transmission settings (p_{interaction} for microscopy-confirmed
- 374 prevalence=0.73, p_{interaction} for PCR-confirmed prevalence=0.73) (**Table 3**).
- 375 In both passive and active pharmacovigilance systems, the frequency of AEs reduced with each
- 376 subsequent cycle and no serious adverse events (SAEs) were detected in either arm (Appendix
- **5**; **Table 4**). Through passive surveillance, 129 AEs were observed in 67/20 887 (0.003%)
- 378 participants of the intervention arm and four AEs were observed in 2/9524 (0.0002%)
- 379 participants of the control arm; all were mild (Appendix 5). Both the frequency and proportion
- 380 of participants who experienced an AE were higher in the intervention arm compared to the
- control arm (p < 0.0001). The most common AEs found in the intervention arm were
- gastrointestinal issues (45.7%), headaches (25.6%), and fever (17.1%).

- 383 Through active surveillance, more participants of the intervention arm reported an AE compared
- to the control arm (13.7% versus 9.4%; p < 0.0001) (**Table 4**). Among children aged <10 years,
- the proportion of reported AEs were similar between arms (10.1% versus 9.4%; p=0.57). In the
- intervention arm, the most common AEs were gastrointestinal issues (41.2%), fever (22.7%), and
- headaches (11.8%). Of the 498 AEs reported in the intervention arm, 64.1% were mild, 32.9%
- 388 were moderate, and 3.0% were severe. Severe AEs included fever (n=7), headache (n=4),
- drowsiness (n=1), vomiting (n=1), diarrhoea (n=1), and loss of appetite (n=1). All AEs appeared
- three hours after drug intake, resolved within 72 hours, and did not require hospitalization. No
- 391 cases of anaemia were found through either passive or active surveillance.
- 392 Of the 597 PCR-positive samples collected from surveys, 433 were successfully genotyped to
- determine molecular markers of antimalarial resistance (Appendix 6). Mutations associated with
- intermediate resistance to SP (PfDHFR N51I, C59R, S108N and PfDHPS A437G) were seen at
- high proportions (range: 58%–100%). PfDHFR I164L was seen at proportions of 2%–12%.
- 396 None of the studied mutations differed in proportions between arms or time periods. There was
- no evidence of PfDHPS K540E, PfDHPS A581G, or PfK13 C580Y mutations.

398 **Discussion**

- 399 We conducted a cluster randomised controlled trial evaluating the safety, coverage, and short-
- term effectiveness of three rounds of MDA with dihydroartemisinin-piperaquine + single low-
- dose primaquine in a low-to-moderate transmission setting of Senegal where malaria control
- 402 interventions were scaled-up through pyrethroid-PBO bednet distribution, three monthly SMC
- 403 cycles, and expansion of year-round proactive community case management of malaria. During
- 404 the trial intervention year, malaria incidence and parasite prevalence reduced in both arms, likely
- due in part to pyrethroid-PBO bednet distribution. In intervention villages, MDA was associated
- 406 with a 55% and 62% reduction in malaria incidence and microscopy-confirmed parasite
- 407 prevalence. Subgroup analyses showed that MDA had a substantial impact on incidence and
- 408 parasite prevalence in those <10 and ≥ 10 years of age and in both low and moderate transmission
- 409 settings. Overall, MDA was well-tolerated; most AEs were mild or moderate and no cases of
- 410 anaemia or SAEs were observed.
- 411 While the trial was not designed to separately estimate MDA's effect on transmission versus its
- 412 direct, prophylactic effect, there was some evidence to suggest that MDA indirectly affected
- transmission. First, subgroup analyses demonstrated that among children under ten, MDA was
- 414 associated with a 46% reduction in incidence as compared to children under ten in the control
- 415 arm who received SMC. We expect that this reduction is unlikely by differences in the
- 416 prophylactic effects of these drugs given we expect dihydroartemisinin-piperaquine and
- 417 sulfadoxine-pyrimethamine + amodiaquine to have similar protective efficacies,¹¹ MDA covered
- 418 less of the transmission season, and MDA had slightly lower coverage than SMC in under tens.
- 419 Moreover, MDA's impact on parasite prevalence further supports this reasoning, given the
- 420 endline survey was conducted more than two months after the last cycle of drug administration
- 421 when the prophylactic effects of both MDA and SMC drugs would have waned.
- 422 Our study has several important findings/caveats. First, our monthly incidence analyses (Figure
 423 4) revealed that SMC should have started one month later and both chemoprevention campaigns

- 424 should have been extended to four cycles to cover the entire transmission season. If this had this
- been done, the impact of MDA in children under tens might not have been as substantial.
- 426 Second, our findings may not be generalisable to most settings deploying SMC where the
- 427 malaria burden is mostly moderate-to-high. While our study found MDA was associated with
- 428 reductions in malaria burden and short-term transmission, evidence of its sustained benefit and
- 429 cost-effectiveness is needed before considering MDA as an intermediate intervention to
- 430 accelerate malaria elimination.
- 431 The WHO currently recommends MDA for transmission reduction in very low-to-low
- transmission settings (i.e., parasite prevalence of <10% or incidence <250 cases/1000
- 433 population). This recommendation is based on evidence from eight cluster randomised controlled
- trials which found MDA can have a substantial, but short-term impact in these settings.^{1,21,22}
- However, MDA is not recommended for transmission reduction in moderate-to-high
- 436 transmission settings, based on evidence from two cluster randomised trials and two non-
- 437 randomized studies which did not show significant short- or long-term impacts on prevalence or
- incidence. Our study provides new evidence indicating MDA may have a short-term impact on
- transmission in both low and moderate transmission strata. Our findings are consistent with a
- recent trial conducted in a moderate transmission setting of The Gambia²³ which demonstrated a
- 441 70% reduction in the odds of PCR-confirmed infection two months after the last MDA cycle.
- 442 Evidence from these two studies should be considered when determining future
- 443 recommendations in moderate transmission settings.
- 444 There were several strengths of the study, including our large sample size, rigorous monitoring
- of safety, and achievement of high coverage. By the final MDA cycle, 70% (21/30) of villages
- reached the WHO target for MDA coverage $(\geq 80\%)^7$, despite significant operational challenges
- 447 in door-to-door drug administration amidst the peak of the global COVID-19 pandemic. The
- high coverage observed in our study was likely attributable to community acceptance of annual
- 449 SMC campaigns, established infrastructure of community case management, support from key
- 450 administrative and health authorities, and repeated community sensitisation campaigns.
- However, absences were common during MDA cycles (14-21%), especially among adolescentsand young adults who are generally asymptomatic and known to be important drivers of
- 452 and young adults who are generally asymptomatic and known to be important drivers of 453 transmission.²⁴ Thus, in order to sustain gains made, future MDA campaigns will need to
- 455 transmission. Thus, in order to sustain gains made, future WDA campaigns will need to 454 consider additional strategies to reach these groups in order to prevent malaria importation and
- 455 potential resurgence after MDA.
- 456 Our study had a few limitations. First, as explained earlier, SMC was not optimally timed,
- 457 making it difficult to draw direct comparisons between SMC and MDA for burden reduction in
- 458 children. Second, baseline incidence was likely non-differentially mismeasured in villages where
- 459 DSDOMs were absent at the start of the study (33% of villages). While the stratified
- 460 randomization scheme balanced this factor between arms, this may have biased our effect
- 461 estimates toward the null (see **Appendix 7** for analyses restricted to villages with prior
- 462 PECADOM+). Third, given baseline incidence was likely mismeasured, subgroup analyses by
- 463 baseline malaria incidence were not reported. Fourth, parasitological confirmation of malaria
- 464 incidence relied on RDT which could have resulted in false positives potentially biasing our
- 465 effect estimates toward the null. Fifth, MDA was conducted for only one year and additional
- 466 cycles may have been needed to reach pre-elimination status (i.e., incidence <5 cases/1000

- 467 population). Finally, the current analyses only evaluated short-term impact. After discontinuation
- of MDA, there is potential for malaria to rebound, and analyses of longer-term impact and cost-
- effectiveness from an additional year of follow-up of these cohorts are forthcoming which will
- 470 help to determine the sustainability of MDA.
- 471 In low-to-moderate malaria transmission settings, where transmission is seasonal and coverage
- 472 of standard malaria control interventions is high, we demonstrated that three cycles of MDA with
- 473 dihydroartemisinin-piperaquine + single-low dose primaquine could safely and rapidly reduce
- 474 malaria burden and potentially have a short-term impact on transmission. However, future work
- investigating whether the impact of MDA can be sustained, and its cost-effectiveness is needed
- to inform countries of the potential of MDA as an intervention to accelerate toward elimination.

477 Role of the funding source

478 The study was funded under the US President's Malaria Initiative Impact Malaria Consortium.

- The funders participated in the design of the study and reviewed the manuscript prior to
- 480 submission. The funders had no role in data collection and data analysis. The first authors had
- 481 full access to the study data and final responsibility for the decision to submit the manuscript.

482 Acknowledgements

- 483 We are grateful to the community of Tambacounda Health District for their participation in the
- 484 study. We thank the health workers, district health staff, the PNLP, and research team at
- 485 Université Iba Der Thiam de Thiès for their contributions in implementing the study and to PMI
- 486 Vectorlink for conducting pyrethroid-PBO bednet distribution and the early village population
- 487 census. We also thank our data safety and monitoring board members Prof Umberto
- 488 D'Alessandro (chair), Prof Jean Guadart, Prof Menno R Smit, Dr Houda Sefiani, and Dr Thomas
- 489 J Peto for their guidance and oversight of the study. We would also like to thank Drs Meera
- 490 Venkatesan, Meghna Desai, and Leah Moriarty for their contributions in the early protocol
- 491 development and study planning, Dr Mame Birame Diouf for his initial coordination and
- 492 strategic engagement of in-country partners, Drs Jean Biyik and Abdoulaye Diop for their
- 493 support in coordinating the pyrethroid-PBO bednet distribution, and Dr Hannah Slater for
- 494 providing the mathematical modelling analysis used for our sample size calculations.

495 **Contributions**

JH conceived of the study and wrote the first draft of the protocol. RG, JLN, MER, AB, KSR,

- 497 JT, EBKC, FB, ST, ID, and ABG contributed to the protocol and approved of the final version.
- EBKC, AD, TG, AS, ST, SG, ACL, ED, ID, OGB, and JLN implemented the study. JLN,
- 499 EBKC, AD, TG, ABG, ST, KSR, MER, MSH, TK, MH, EE, RG, DS, and FB provided
- 500 oversight of the study. ACL conducted laboratory analysis of samples. The statistical analysis
- 501 plan was developed by MSH, PM, AF, MER, AB, EBKC, and JLN and data were analysed by
- 502 AF with XW, MER, AS, and EBKC. MER, EBKC, AF, XW, PM, AB, JH, KSR, MSH, and JLN
- interpreted the results. MER, EBKC, MSH, and JLN wrote the first draft of the manuscript. PM,
- 504 JH, AF, and KSR provided additional inputs to the writing. All authors reviewed and approved
- the final manuscript before submission.

506 **Declaration of interests**

- 507 The study was funded by the US President's Malaria Initiative. MER is supported by the Eunice
- 508 Kennedy Shriver National Institute of Child Health & Human Development of the National
- 509 Institutes of Health (Award Number K99HD111572). JH and ABG receive salary support from
- the US President's Malaria Initiative. The findings and conclusions in this report are those of the
- authors and do not necessarily represent the official position of the National Institutes of Health,
- 512 US Centers of Disease Control and Prevention, and the US Agency for International
- 513 Development.

514 Data sharing

- 515 De-identified data may be available upon reasonable request and approval from Principal
- 516 Investigators via a data sharing agreement.


517 **References**


- World Health Organization. WHO guidelines for malaria, 3 June 2022: World Health
 Organization, 2022.
- 520 2. SMC Alliance. 53 million children living in 18 countries covered with Seasonal Malaria
- 521 Chemoprevention in 2023. April 5, 2024 2024. https://www.smc-alliance.org/53-million-
- 522 <u>children-living-in-18-countries-covered-with-seasonal-malaria-chemoprevention-in-2023</u>
- 523 (accessed July 17, 2024.
- 524 3. Cairns M, Ceesay SJ, Sagara I, et al. Effectiveness of seasonal malaria chemoprevention
- (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. *PLoS Med* 2021; **18**(9): e1003727.
- 527 4. World Health Organization. World Malaria Report 2022. Geneva, Switzerland: World
 528 Health Organization; 2022.
- 5. Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria and its operational challenges. *Am J Trop Med* 2015; **93**(1): 125.
- 531 6. Shah MP, Hwang J, Choi L, Lindblade KA, Kachur SP, Desai M. Mass drug
- administration for malaria. *The Cochrane Database of Systematic Reviews* 2021; **2021**(9).
- 533 7. World Health Organization. Mass drug administration for falciparum malaria: a practical534 field manual. 2017.
- Sagara I, Zongo I, et al. Evaluation of seasonal malaria chemoprevention in
 two areas of intense seasonal malaria transmission: secondary analysis of a household-
- 536 two areas of intense seasonal mataria transmission: secondary analysis of a nousehold-527 randomized placebo controlled trial in Houndá District. Burking Esso and Bougouni Distr
- randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District,
 Mali. *PLoS Med* 2020; **17**(8): e1003214.
- NDiaye J, Cissé B, Ba E, et al. Safety of seasonal malaria chemoprevention (SMC) with
 sulfadoxine-pyrimethamine plus amodiaquine when delivered to children under 10 years of age
- 541 by district health services in Senegal: results from a stepped-wedge cluster randomized trial.
- 542 *PLoS One* 2016; **11**(10): e0162563.
- 543 10. Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and
- efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of
 malaria: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**(2): 184-93.
- 546 11. Zongo I, Milligan P, Compaore YD, et al. Randomized noninferiority trial of
- dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for
 seasonal malaria chemoprevention in Burkina Faso. *Antimicrob Agents Chemother* 2015; **59**(8):
 4387-96.
- 550 12. Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene 551 blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind,
- randomised controlled trial. *Lancet Infect Dis* 2018; **18**(6): 627-39.
- 553 13. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-
- lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. *J Infect Dis* 2013; 207(11):
 1637-45.
- 556 14. World Health Organization. Policy brief on single-dose primaquine as a gametocytocide557 in Plasmodium falciparum malaria: World Health Organization, 2015.
- 558 15. Stepniewska K, Humphreys GS, Gonçalves BP, et al. Efficacy of single-dose primaquine
- with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission:
- an individual patient meta-analysis. *J Infect Dis* 2022; **225**(7): 1215-26.

561 16. Eisele TP, Bennett A, Silumbe K, et al. Short-term impact of mass drug administration

- with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a clusterrandomized controlled trial. *J Infect Dis* 2016; **214**(12): 1831-9.
- 564 17. Griffin JT. The interaction between seasonality and pulsed interventions against malaria 565 in their effects on the reproduction number. *PLoS Comput Biol* 2015; **11**(1): e1004057.
- 566 18. Amoah LE, Opong A, Ayanful-Torgby R, Abankwa J, Acquah FK. Prevalence of G6PD
- deficiency and Plasmodium falciparum parasites in asymptomatic school children living in
 southern Ghana. *Malar J* 2016; **15**(1): 1-8.
- 569 19. Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, Jaton K. Detection of four
- 570 Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-571 specific real-time PCR assays. *J Clin Microbiol* 2004; **42**(12): 5636-43.
- specific real-time PCR assays. *J Clin Microbiol* 2004; 42(12): 5636-43.
 Chomarat M, Breysse F. Technique d'analyse des courbes de fusion haut
- 572 20. Chomarat M, Breysse F. Technique d'analyse des courbes de fusion haute résolution
 573 (FHR) ou High Resolution Melting analysis (HRM) en infectiologie. *Immuno-Anal Biol Spe*574 2011; 26(4): 207-11.
- 575 21. Schneider ZD, Shah MP, Boily MC, et al. Mass Drug Administration to Reduce Malaria
- Transmission: A Systematic Review and Meta-Analysis. *Am J Trop Med* 2023: tpmd220766tpmd.
- 578 22. Malaria Policy Advisory Committee. Meeting report of the Evidence Review Group on
 579 mass drug administration, mass screening and treatment and focal screening and treatment for
 580 malaria (20–22 April 2015). Geneva, Switzerland, 2015.
- 581 23. Dabira ED, Soumare HM, Conteh B, et al. Mass drug administration of ivermectin and
- dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard
 control interventions: a cluster-randomised controlled trial in The Gambia. *Lancet Infect Dis*
- 584 2022; **22**(4): 519-28.
- 58524.Rek J, Blanken SL, Okoth J, et al. Asymptomatic school-aged children are important
- drivers of malaria transmission in a high endemicity setting in Uganda. *J Infect Dis* 2022; 226(4):
 708-13.
- 588


589 Figures






Abbreviations: MDA = mass drug administration; PBO = piperonyl butoxide; PECADOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

590 Figure 2. Trial profile



Abbreviations: HP = health post; MDA = mass drug administration; PECADOM+ = Prise en Charge à Domicile Plus (i.e., proactive community case management of malaria); SMC = seasonal malaria chemoprevention

- 591 Figure 3. Graphical representation of village-level monthly incidence of symptomatic malaria
- during the intervention implementation year by intervention group (A) and stratified by age
- 593 group (B), and baseline transmission intensity (C).



Abbreviations: MDA = mass drug administration; SMC = seasonal malaria chemoprevention Monthly incidence rates and corresponding 95% confidence intervals, represented by points and bars, respectively, were calculated using a random effects Poisson model with village-level random intercepts to account for clustered observations.

Tables 594

Table 1. Trial profile 595

Characteristics	Total	Intervention (MDA)	Control
Village-level ¹			
Number of clusters (villages)	60	30	30
Villages by health post, n (%)			
Bohe	9 (15%)	6 (20%)	3 (10%)
Dar Salam	2 (3%)	1 (3%)	1 (3%)
Dawadi	14 (23%)	6 (20%)	8 (27%)
Koussanar	9 (15%)	5 (17%)	4 (13%)
Missirah	6 (10%)	2 (7%)	4 (13%)
Neteboulou	5 (8%)	2 (7%)	3 (10%)
Sinthiou Maleme	15 (25%)	8 (27%)	7 (23%)
Presence of DSDOM prior to the study, n (%)			
No	20 (33%)	10 (33%)	10 (33%)
Yes	40 (67%)	20 (67%)	20 (67%)
Distance to health post in km, mean (SD)	14.8 (8.4)	14.9 (8.6)	14.6 (8.3)
Population size in 2019 ² , mean (SD)	322 (168)	330 (170)	315 (168)
Population size <10 years of age in 2019 ² , mean (SD)	119 (62)	120 (63)	117 (62)
% Population <10 years of age in 2019, mean (SD)	37% (5)	36% (4)	37% (6)
Baseline microscopy prevalence (%), mean (SD)	8% (8)	7% (9)	9% (8)
Individual-level Characteristics from Baseline Survey	v, n (%)		
Participant age in years			
<10 years of age	783 (33%)	373 (32%)	410 (35%)
≥ 10 years of age	1578 (67%)	809 (68%)	769 (65%)
Participant sex		. ,	. ,
Male	1180 (50%)	576 (49%)	604 (51%)
Female	1182 (50%)	607 (51%)	575 (49%)
Slept away from home in the past 15 days			
Yes	459 (20%)	245 (21%)	214 (19%)
No	1846 (80%)	910 (79%)	936 (81%)
Type of bed net used		. ,	. ,
None	37 (2%)	28 (2%)	9 (1%)
Pyrethroid-PBO ITN	2282 (98%)	1131 (96%)	1151 (99%)
Non-pyrethroid-PBO ITN	21 (1%)	20 (2%)	1 (0.1%)
Received the most recent cycle of SMC? ³	. ,	、 ,	. ,
No	169 (20%)	94 (23%)	75 (17%)
Yes	687 (81%)	316 (77%)	371 (83%)
Completed all three cycles of SMC in 2020? ³			
No	248 (29%)	128 (31%)	120 (27%)
Yes	610 (71%)	284 (69%)	326 (73%)

Abbreviations: ITN = insecticide-treated net; MDA = mass drug administration; PBO = piperonyl butoxide; SD = standard deviation; SMC = seasonal malaria chemoprevention

¹ Village-level variables used in constrained randomization scheme.
 ² Incidence estimates provided by Tambacounda Regional District Office.
 ³ Assessed only among children <10 years of age.

	Averag	e incidence per 1	1,000 (events / pop	Intervention effect,			
Study outcomes	Intervention (MDA)		Control		1-ratio of IRRs [95% CI] ¹		
•	2020	2021	2020	2021	Unadjusted	Adjusted ²	
Primary outcome							
Incidence among all ages	181 (2067/10745)	93 (924/10745)	204 (1883/9641)	173 (1751/9641)	52% [21%, 71%]	55% [28%, 72%]	
<10 years old	133 (514/4091)	84 (287/4091)	154 (515/3598)	120 (463/3598)	43% [3%, 66%]	46% [10%, 67%]	
≥ 10 years and older	213 (1553/6637)	100 (633/6637)	236 (1368/5991)	206 (1287/5991)	55% [27%, 73%]	58% [33%, 74%]	
Subgroup analyses							
Among children <10 years	of age						
<5 years of age	102 (163/1939)	69 (115/1939)	133 (208/1723)	93 (166/1723)	29% [-35%, 62%]	31% [-25%, 62%]	
5 to <10 years of age	85 (351/2152	61 (172/2152)	118 (307/1875	85 (297/1875)	43% [-4%, 69%]	45% [4%, 68%]	
Baseline transmission inter	nsity ³						
Low (<10%)	172 (1508/8316)	83 (658/8316)	228 (1385/6463)	171 (1085/6463)	53% [25%, 71%]	55% [31%, 71%]	
Moderate (≥10%)	214 (559/2429)	125 (266/2429)	148 (498/3178)	178 (666/3178)	49% [-48%, 82%]	52% [-19%, 81%]	

596	Table 2. RDT-confirmed	l malaria incidence a	nd intervention	effectiveness	estimates durin	g peak transmission	season (July-December)
-----	------------------------	-----------------------	-----------------	---------------	-----------------	---------------------	------------------------

Abbreviations: IRR = incidence rate ratio; MDA = mass drug administration

¹ Intervention effect estimated using mixed effects Poisson regression with village-level random intercepts.

 2 Adjusted for DSDOM at baseline, village population size of children <10 years of age, distance from health post, baseline parasite prevalence by microscopy, and village population size in 2019, and presence of DSDOM at time of case detection.

³ Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for "Low" transmission clusters and \geq 10% for "Moderate" transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to "Low" category; 7 clusters in intervention arm and 9 clusters in control arm contributed to "Moderate" category.

		Mean prevale	Intervention effect,				
Outcomes	Interven	Intervention (MDA)		ontrol	1-ratio of PRs [95% CI] ¹		
	2020	2021	2020	2021	Unadjusted	Adjusted ²	
Microscopy-detected infec	ctions						
All ages	6·1% [2·8%, 9·4%]	1.8% [0.8%, 2.9%]	6·7% [4·0%, 9·4%]	4·7% [2·5%, 6·9%]	61% [21%, 81%]	62% [22%, 80%]	
< 10 years old	8·2% [2·7%, 13·7%]	1.3% [0.2%, 2.4%]	7·3% [3·1%, 11·6%]	4.5% [2.0%, 7.0%]	76% [41%, 90%]	76% [42%, 90%]	
\geq 10 years and older	5.1% [2.6%, 7.7%]	2·2% [0·7%, 3·6%]	6·4% [3·9%, 8·8%]	4·8% [1·8%, 7·9%]	50% [-16%, 79%]	51% [-14%, 79%]	
Baseline transmission inten	sity ³						
Low (<10%)	2.6% [1.3%, 3.9%]	1.0% [0.2%, 1.8%]	3·4% [2·1%, 4·8%]	4·3% [1·4%, 7·2%]	63% [-1%, 86%]	62% [0%, 86%]	
Moderate (≥10%)	18·8% [9·4%, 28·2%]	5·0% [2·1%, 7·8%]	17·1% [12·5%, 21·8%]	6·0% [3·4%, 8·6%]	54% [18%, 73%]	56% [22%, 75%]	
PCR-detected infections							
All ages	17·9% [11·3%, 24·4%]	4.5% [2.5%, 6.4%]	19·9% [11·8%, 28·1%]	8·3% [4·8%, 11·7%]	46% [-3%, 70%]	47% [3%, 71%]	
< 10 years old	18·6% [10·9%, 26·4%]	2·3% [0·6%, 3·9%]	19·6% [9·9%, 29·4%]	5·1% [2·2%, 8·0%]	71% [34%, 87%]	71% [35%, 87%]	
\geq 10 years and older	17·5% [11·0%, 24·0%]	5·8% [2·9%, 8·6%]	20·1% [11·7%, 28·5%]	10·2% [5·2%, 15·3%]	33% [-27%, 64%]	33% [-27%, 65%]	
Baseline transmission inten	sity ³						
Low (<10%)	14·0% [7·9%, 20·1%]	3·0% [1·0%, 5·0%]	14·3% [6·3%, 22·3%]	4·7% [2·4%, 6·9%]	48% [-4%, 74%]	47% [-7%, 74%]	
Moderate (≥10%)	32.0% [11.4%, 52.5%]	9·9% [6·1%, 13·7%]	38·0% [21·7%, 54·4%]	18·7% [12·2%, 25·3%]	37% [2%, 59%]	40% [9%, 60%]	

597 Table 3. Secondary outcomes of parasite prevalence.

Abbreviations: MDA = mass drug administration; PCR = polymerase chain reaction; PR = prevalence ratio

¹ Intervention effect estimated using Poisson regression with robust standard errors. Survey weights incorporated to account for two-stage sampling design (by household and household size).

 2 Adjusted for variables included in constrained randomisation: presence of DSDOM at baseline, village population size of children <10 years of age, distance from health post, and village population size in 2019.

³ Transmission intensity was defined as baseline village-level microscopy-confirmed parasite prevalence of <10% for "Low" transmission clusters and \geq 10% for "Moderate" transmission clusters. 23 clusters from the intervention arm and 21 clusters from the control arm contributed to "Low" category; 7 clusters in

intervention arm and 9 clusters in control arm contributed to "Moderate" category.

Active Surveillance	Intervention (MDA)	Control (SMC)	p-valu					
Among all participants surveyed								
Participants with any AE, n/N (%)								
All cycles	260/1903 (13.7%)	152/1616 (9.4%)	<0.0001					
First cycle	124/619 (20.0%)	93/569 (16.3%)	0.10					
Second cycle	94/628 (15.0%)	51/563 (9.1%)	0.002					
Third cycle	42/656 (6.4%)	8/484 (1.7%)	<0.0001					
Frequency of adverse events, n								
All cycles	498	310						
First cycle	229	175						
Second cycle	181	119						
Third cycle	88	16						
Most common adverse events, n/N (%)								
Gastrointestinal issues ²	205/498 (41.2%)	144/310 (46.5%)	0.16					
Fever	113/498 (22.7%)	109/310 (35.2%)	<0.001					
Headaches	59/498 (11.8%)	20/310 (6.5%)	0.017					
Drowsiness	26/498 (5.2%)	8/310 (2.6%)	0.102					
Other	95/498 (19.1%)	29/310 (9.4%)	<0.001					
Severity of AEs, n/N (%)								
Mild	319/498 (64.1%)	178/310 (57.4%)	0.059					
Moderate	164/498 (32.9%)	118/310 (38.1%)	0.055					
Severe	15/498 (3·0%)	14/310 (4.5%)	0.26					
Any serious AE, n/N (%)	0/498 (0%)	0/310 (0%)						
Among children <10 years of age	0/ 190 (0/0)	0/510(0/0)						
Participants with any AE, n/N (%)								
All cycles	85/841 (10.1%)	145/1544 (9.4%)	0.57					
First cycle	36/259 (13.9%)	90/547 (16.5%)	0.37					
Second cycle	33/271 (12·2%)	47/529 (8.9%)	0.33					
Third cycle	16/311 (5·1%)	8/468 (1.7%)	0.14					
Frequency of adverse events, n	10/311 (3.1%)	0/400 (1.1%)	0.007					
	176	296						
All cycles								
First cycle	68	170						
Second cycle	67	110						
Third cycle	41	16						
Most common adverse events, n/N (%)								
Gastrointestinal issues ²	87/176 (49.4%)	136/296 (45.9%)	0.523					
Fever	50/176 (28.4%)	106/296 (35.8%)	0.121					
Headache	10/176 (5.7%)	19/296 (6.4%)	0.901					
Drowsiness	2/176 (1.1%)	8/296 (2.7%)	0.334					
Other	27/176 (15.3%)	27/296 (9.1%)	0.0057					
Severity of AEs, n/N (%)	21/110 (13.370)	21/270 (7.170)	0.0037					
Mild	102/176 (58.0%)	169/296 (57.1%)	0.86					
	· ,	, ,						
Moderate	69/176 (39·2%)	115/296 (38.9%)	0.94					
Severe	5/176 (2.8%)	12/296 (4.1%)	0.49					
Any serious AE, n/N (%)	0/176 (0%)	0/296 (0%)						

598 Table 4. Safety outcomes monitored through active surveillance

¹P-value computed using Chi-squared test or Fisher's exact test (if frequency of any cell value was <5)

 2 Defined as one of the following AEs: nausea, vomiting, diarrhoea, abdominal pain, or loss of appetite.